<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-5555</issn>
      <issn pub-type="epub">1432-0584</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25135451</article-id>
      <article-id pub-id-type="pmc">4317506</article-id>
      <article-id pub-id-type="publisher-id">2191</article-id>
      <article-id pub-id-type="doi">10.1007/s00277-014-2191-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Preexisting <italic>TP53</italic> mutation in therapy-related acute myeloid leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Schulz</surname>
            <given-names>Eduard</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kashofer</surname>
            <given-names>Karl</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heitzer</surname>
            <given-names>Ellen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mhatre</surname>
            <given-names>Ketaki N.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Speicher</surname>
            <given-names>Michael R.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hoefler</surname>
            <given-names>Gerald</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sill</surname>
            <given-names>Heinz</given-names>
          </name>
          <address>
            <phone>+ 43 316 385 80257</phone>
            <email>heinz.sill@medunigraz.at</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Division of Hematology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 38D, A-8036 Graz, Austria </aff>
        <aff id="Aff2"><label/>Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25/1, A-8036 Graz, Austria </aff>
        <aff id="Aff3"><label/>Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/VIII, A-8010 Graz, Austria </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>20</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2015</year>
      </pub-date>
      <volume>94</volume>
      <fpage>527</fpage>
      <lpage>529</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2014</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Therapy-related myeloid neoplasms</kwd>
        <kwd>
          <italic>TP53</italic>
        </kwd>
        <kwd>Leukemogenesis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>Therapy-related myeloid neoplasms (t-MNs) are a unique clinical entity occurring as late complication of chemotherapy and radiotherapy administered for a primary disease [<xref ref-type="bibr" rid="CR1">1</xref>]. According to the WHO classification, t-MNs are thought to be due to mutational events in hematopoietic stem and precursor cells (HSPCs) induced by these treatments [<xref ref-type="bibr" rid="CR2">2</xref>]. However, no consistent biomarker has been identified yet that classifies a particular neoplasm as &#x201C;therapy-related&#x201D; [<xref ref-type="bibr" rid="CR3">3</xref>]. This raises the possibility that other mechanisms may also be operational in their pathogenesis. We and others [<xref ref-type="bibr" rid="CR4">4</xref>], therefore, hypothesized that mutations contributing to leukemic transformation were preexisting in HSPCs of some of these individuals.</p>
    <p>In this study, we selected patients with therapy-related AML (t-AML) following cytotoxic treatment of malignant lymphomas as bone marrow (BM) biopsies are routinely performed during their initial staging procedures. We focused on the <italic>TP53</italic> gene which is frequently mutated in t-AMLs exhibiting a potentially important role in leukemogenesis [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>]. We identified a somatic heterozygous 64-base pair duplication (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>) in a 71&#xA0;year-old male Caucasian patient who suffered from Hodgkin lymphoma 13&#xA0;years ago treated by chemotherapy and radiotherapy. To search for potential cooperating mutations, we performed Ion Torrent deep sequencing of recurrently mutated genes in AML [<xref ref-type="bibr" rid="CR8">8</xref>]. However, no further mutations could be identified (see <xref ref-type="sec" rid="Sec1">Supplementary Information</xref> for list of genes).<fig id="Fig1"><label>Fig. 1</label><caption><p>Detection of a preexisting <italic>TP53</italic> mutation in a patient with therapy-related acute myeloid leukemia (t-AML). <bold>a</bold> Bi-directional Sanger sequencing demonstrates the leukemia-specific 64&#xA0;bp duplication in exon 4 of the <italic>TP53</italic> gene. <bold>b</bold> The primer pair enables the detection of the duplication to a dilution of 0.01&#xA0;% t-AML DNA in normal control DNA. Analysis of four AML control samples revealed the absence of this duplication in all of them (data not shown). <bold>c</bold> The 62-base pair product (upper band) specific for the <italic>TP53</italic> duplication could be detected in the bone marrow (BM) obtained at diagnosis of Hodgkin lymphoma as well as in a lymphadenitis specimen (LN) the latter obtained 20&#xA0;years before diagnosis of t-AML. The lower band refers to primer dimers, <italic>GAPDH</italic> (lower gel) served as control gene for DNA integrity. <bold>d</bold> Expansion of cells with the <italic>TP53</italic> duplication determined by digital PCR. Relative ratios between mutant <italic>TP53</italic> fragments and <italic>BRAF</italic> wild-type fragments were assessed using the QuantStudio 3D Digital PCR System (Life Technologies, Carlsbad, CA). Copy number changes at the <italic>BRAF</italic> locus of the t-AML were excluded using low coverage whole genome sequencing to ensure that <italic>BRAF</italic> is suitable as a reference and not subjected to copy number changes. Data shown are means of assays performed in duplicates and error bars indicate 95&#xA0;% confidence intervals. <italic>BM</italic> bone marrow; <italic>LN</italic> lymphadenitis sample; <italic>NTC</italic> no template control; <italic>WGA</italic> whole genome amplified DNA</p></caption><graphic xlink:href="277_2014_2191_Fig1_HTML" id="MO1"/></fig></p>
    <p>We established a highly sensitive PCR assay specific for this rearrangement (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>) and could unambiguously demonstrate the presence of the <italic>TP53</italic> mutation in the patient&#x2019;s BM obtained at the time of the lymphoma staging (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). Surprisingly, the <italic>TP53</italic> duplication was also detected in a reactive lymphadenitis sample obtained 7&#xA0;years before lymphoma diagnosis (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). To further demonstrate that expansion of the <italic>TP53</italic> mutated clone occurred following cytotoxic treatment, we quantified the <italic>TP53</italic> duplication by digital PCR (dPCR) which showed that the relative proportion of mutated cells increased substantially in the t-AML specimen (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>). It, furthermore, confirmed the <italic>TP53</italic> duplication being a somatically acquired event as it was absent from a skin biopsy obtained at the time of the leukemia diagnosis.</p>
    <p>In the case report presented here, we were able to demonstrate that cytotoxic treatment did not induce a leukemia-specific mutation but rather may have facilitated the expansion of a pre-leukemic clone harboring a somatic <italic>TP53</italic> mutation. Since dPCR data quantifying the <italic>TP53</italic> duplication were comparable in lymph node and pretreatment BM, the mutation might have occurred in HSPCs that retained their lymphoid as well as myeloid differentiation potential and remained dormant for many years. This finding challenges current concepts of therapy-related leukemogenesis and is in line with data presented at the 2013 annual meeting of the American Society of Hematology [<xref ref-type="bibr" rid="CR4">4</xref>]. There, somatic <italic>TP53</italic> variants could be identified at low frequencies in mobilized peripheral blood leukocytes of two t-MDS/t-AML cases years before diagnosis. However, in clinical practice, HSPC harvests from peripheral blood are performed following intense chemotherapy including application of recombinant granulocyte-colony factor. Here, we provided definitive evidence that a leukemia-specific mutation could be found in HSPCs before any cytotoxic treatment was administered.</p>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec1">
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="277_2014_2191_MOESM1_ESM.pdf">
            <label>ESM 1</label>
            <caption>
              <p>(PDF 283&#xA0;kb)</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>The work was funded in part by the Austrian National Bank, Anniversary Fund (grant no. 13918), Land Steiermark, Leuk&#xE4;miehilfe Steiermark and &#x201C;Vereinigung Forschungsf&#xF6;rderung&#x201D; at Medical University of Graz, Austria. E.S. is supported by a dissertational grant from the Austrian Society of Hematology and Oncology.</p>
      <sec id="d30e410">
        <title>Ethical standards statement</title>
        <p>The study was approved by the ethics committee of the Medical University of Graz, Austria, and written informed consent was obtained from all patients.</p>
      </sec>
      <sec id="d30e415">
        <title>Authorship</title>
        <p>E.S., K.K., E.H., M.R.S., G.H. and H.S. conceived experiments. K.M. and E.S. performed Sanger sequencing. K.K. performed and analyzed targeted deep sequencing. E.H. performed and analyzed dPCR. G.H. and H.S. provided patient samples. E.S. and H.S. had full access to all of the data in the study and take responsibility for their integrity and the accuracy of the data analysis. E.S. and H.S. wrote the manuscript which was approved by all authors.</p>
      </sec>
      <sec id="d30e420">
        <title>Conflict of interest</title>
        <p>The authors declare no competing financial interests.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Churpek</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>The evolving challenge of therapy-related myeloid neoplasms</article-title>
          <source>Best Pract Res Clin Haematol</source>
          <year>2013</year>
          <volume>26</volume>
          <issue>4</issue>
          <fpage>309</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beha.2013.09.001</pub-id>
          <pub-id pub-id-type="pmid">24507808</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Vardiman</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Arber</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Brunning</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Matutes</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Therapy-related myeloid neoplasms</article-title>
          <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>
          <year>2008</year>
          <edition>4</edition>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>IARC</publisher-name>
          <fpage>127</fpage>
          <lpage>129</lpage>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mauritzson</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Albin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rylander</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Billstrom</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ahlgren</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mikoczy</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Bjork</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stromberg</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Mitelman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hagmar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976&#x2013;1993 and on 5098 unselected cases reported in the literature 1974&#x2013;2001</article-title>
          <source>Leukemia</source>
          <year>2002</year>
          <volume>16</volume>
          <issue>12</issue>
          <fpage>2366</fpage>
          <lpage>2378</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2402713</pub-id>
          <pub-id pub-id-type="pmid">12454741</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>TN</given-names>
            </name>
            <name>
              <surname>Ramsingh</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lamprecht</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Heath</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fulton</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Mardis</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Westervelt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Welch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Graubert</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>DiPersio</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Druley</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Link</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>The role of early TP53 mutations on the evolution of therapy-related AML</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>122</volume>
          <issue>21</issue>
          <fpage>5</fpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shih</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Dolezal</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Abdel-Wahab</surname>
              <given-names>OI</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Nimer</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Klimek</surname>
              <given-names>VM</given-names>
            </name>
          </person-group>
          <article-title>Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia</article-title>
          <source>Haematologica</source>
          <year>2013</year>
          <volume>98</volume>
          <issue>6</issue>
          <fpage>908</fpage>
          <lpage>912</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2012.076729</pub-id>
          <pub-id pub-id-type="pmid">23349305</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schulz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Valentin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ulz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beham-Schmid</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lind</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rupp</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lackner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wolfler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zebisch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Olipitz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Geigl</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Berghold</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Speicher</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Sill</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms</article-title>
          <source>J Med Genet</source>
          <year>2012</year>
          <volume>49</volume>
          <issue>7</issue>
          <fpage>422</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100674</pub-id>
          <pub-id pub-id-type="pmid">22652532</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zuber</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Diaz-Flores</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lintault</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kogan</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>P53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal</article-title>
          <source>Genes Dev</source>
          <year>2010</year>
          <volume>24</volume>
          <issue>13</issue>
          <fpage>1389</fpage>
          <lpage>1402</lpage>
          <pub-id pub-id-type="doi">10.1101/gad.1940710</pub-id>
          <pub-id pub-id-type="pmid">20595231</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Cancer Genome Atlas Research Network</collab>
          </person-group>
          <article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <issue>22</issue>
          <fpage>2059</fpage>
          <lpage>2074</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1301689</pub-id>
          <pub-id pub-id-type="pmid">23634996</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
